Palonosetron: interakcje

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Amfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina, Interakcje z innymi lekami)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina + nalokson, Interakcje z innymi lekami)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina + kodeina, Interakcje z innymi lekami)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Butalbital + paracetamol + kofeina + kodeina, Interakcje z innymi lekami)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Butorfanol, Środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (etykieta leku Deksamfetamina, Ostrzeżenia)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Łączenie dziurawca z lekami przeciwdepresyjnymi i innymi lekami serotoninergicznymi zwiększa ryzyko zespołu serotoninowego. (NCCIH, St. John's Wort)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon, Interakcje z innymi lekami)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + chlorfenamina, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + homatropina, Interakcje z innymi lekami)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + ibuprofen, Środki ostrożności)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + paracetamol, Środki ostrożności)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydromorfon, Interakcje z innymi lekami)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Kodeina, Interakcje z innymi lekami)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Leworfanol, Środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Lisdeksamfetamina, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Metadon, Ostrzeżenia i środki ostrożności)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (etykieta leku Metaksalon, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Metamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Morfina, Interakcje z innymi lekami)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (etykieta leku Oksykodon, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Oksymorfon, Interakcje z innymi lekami)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Olicerydyna, Interakcje z innymi lekami)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Paracetamol + kodeina, Środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Pentazocyna + nalokson, Środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Pokrzyk wilcza jagoda (belladonna) + opium, Interakcje z innymi lekami)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Prometazyna + kodeina, Interakcje z innymi lekami)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Remifentanyl, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Zyprazydon, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (etykieta leku Nalbufina, Interakcje z innymi lekami)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (etykieta leku Fentermina, Ostrzeżenia i środki ostrożności)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (etykieta leku Oksykodon + paracetamol, Interakcje z innymi lekami)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)